FMC Corporation Reports 7% Revenue Growth Amid Strong Cash Generation

PHILADELPHIA, Pa. — FMC Corporation (NYSE: FMC) announced a 7% year-over-year revenue increase to $1.22 billion for the fourth quarter of 2024, driven by volume growth in its growth portfolio. Despite foreign exchange (FX) headwinds and lower pricing, the company reported a significant improvement in cash flow, with over $1 billion generated from operations.

“We delivered solid sales and strong year-on-year adjusted EBITDA growth in the quarter,” said Pierre Brondeau, FMC chairman and CEO. “While volume growth was below expectations due to reduced customer inventory levels, our growth portfolio and cost discipline helped us achieve a 33% increase in adjusted EBITDA.”

FMC’s fourth-quarter performance was bolstered by a 15% increase in volume, particularly in the United States. However, a 5% FX headwind, primarily due to the Brazilian Real, and a 3% price decline tempered overall growth. Sales of products launched in the last five years surged 24%, driven by new active ingredients fluindapyr and Isoflex™.

Regionally, North America saw a 23% sales increase, while Latin America experienced a 10% decline, though sales rose 2% excluding currency impacts. Asia and EMEA reported 10% and 18% growth, respectively, with the Plant Health business jumping 33% year-over-year.

For the full year, FMC’s revenue declined 5% to $4.25 billion, with a 3% organic revenue drop after adjusting for FX impacts. The company attributed the decline to a 6% price drop and a 2% FX headwind, partially offset by a 3% volume increase. Adjusted earnings per share for the year fell 8% to $3.48.

Looking ahead, FMC forecasts 2025 revenue between $4.15 billion and $4.35 billion, with adjusted EBITDA expected to range from $870 million to $950 million. The company anticipates volume growth to offset weaker demand, though price declines and FX headwinds remain challenges.

FMC’s strong cash generation in 2024, with $737 million from operations and $614 million in free cash flow, reflects improved payables and reduced inventory levels. However, free cash flow is expected to normalize in 2025, with projections between $200 million and $400 million.